| Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial J Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, ... Jama 321 (1), 69-79, 2019 | 1076 | 2019 |
| How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial SE Inzucchi, B Zinman, D Fitchett, C Wanner, E Ferrannini, ... Diabetes care 41 (2), 356-363, 2018 | 670 | 2018 |
| Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease C Wanner, JM Lachin, SE Inzucchi, D Fitchett, M Mattheus, J George, ... Circulation 137 (2), 119-129, 2018 | 613* | 2018 |
| Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial J Rosenstock, SE Kahn, OE Johansen, B Zinman, MA Espeland, ... Jama 322 (12), 1155-1166, 2019 | 582 | 2019 |
| The kisspeptin-GnRH pathway in human reproductive health and disease K Skorupskaite, JT George, RA Anderson Human reproduction update 20 (4), 485-500, 2014 | 507 | 2014 |
| Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials J Rosenstock, J Marquard, LM Laffel, D Neubacher, S Kaspers, ... Diabetes care 41 (12), 2560-2569, 2018 | 314 | 2018 |
| Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial D Fitchett, SE Inzucchi, CP Cannon, DK McGuire, BM Scirica, ... Circulation 139 (11), 1384-1395, 2019 | 298 | 2019 |
| Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial D Fitchett, J Butler, P van de Borne, B Zinman, JM Lachin, C Wanner, ... European heart journal 39 (5), 363-370, 2018 | 267 | 2018 |
| The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study WG Herrington, D Preiss, R Haynes, M von Eynatten, N Staplin, ... Clinical kidney journal 11 (6), 749-761, 2018 | 247 | 2018 |
| Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved … SD Anker, J Butler, GS Filippatos, W Jamal, A Salsali, J Schnee, K Kimura, ... European journal of heart failure 21 (10), 1279-1287, 2019 | 229 | 2019 |
| Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men JT George, JD Veldhuis, AK Roseweir, CL Newton, E Faccenda, RP Millar, ... The Journal of Clinical Endocrinology & Metabolism 96 (8), E1228-E1236, 2011 | 197 | 2011 |
| The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors J Butler, CE Hamo, G Filippatos, SJ Pocock, RA Bernstein, M Brueckmann, ... European journal of heart failure 19 (11), 1390-1400, 2017 | 183 | 2017 |
| Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG … N Sattar, D Fitchett, S Hantel, JT George, B Zinman Diabetologia 61, 2155-2163, 2018 | 175 | 2018 |
| Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications J Young, JT George, JA Tello, B Francou, J Bouligand, ... Neuroendocrinology 97 (2), 193-202, 2013 | 168 | 2013 |
| Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA DK McGuire, JH Alexander, OE Johansen, V Perkovic, J Rosenstock, ... Circulation 139 (3), 351-361, 2019 | 164 | 2019 |
| Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME S Verma, CD Mazer, M Al-Omran, SE Inzucchi, D Fitchett, U Hehnke, ... Circulation 137 (4), 405-407, 2018 | 163 | 2018 |
| Physiology of GNRH and gonadotropin secretion P Marques, K Skorupskaite, KS Rozario, RA Anderson, JT George Endotext [internet], 2022 | 156 | 2022 |
| Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control SE Inzucchi, M Kosiborod, D Fitchett, C Wanner, U Hehnke, S Kaspers, ... Circulation 138 (17), 1904-1907, 2018 | 156 | 2018 |
| Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease―results from EMPA-REG OUTCOME®― K Kaku, J Lee, M Mattheus, S Kaspers, J George, HJ Woerle, ... Circulation journal 81 (2), 227-234, 2017 | 141 | 2017 |
| Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes JT George, RP Millar, RA Anderson Neuroendocrinology 91 (4), 302-307, 2010 | 136 | 2010 |
Christoph WannerWürzburg UniversityVerified email at medizin.uni-wuerzburg.de
